OX27 / Orexo - LARVOL DELTA

Clinical Application of Metagenomic Next-Generation Sequencing (mNGS) in Patients with Early Pulmonary Infection After Liver Transplantation. (PubMed, Infect Drug Resist) - "Among the three drug-resistant bacteria that showed positivity in mNGS and traditional culture, the presence of drug-resistance genes-mecA in Staphylococcus aureus; KPC-2, KPC-9, KPC-18, KPC-26, OXA27, OXA423 in Klebsiella pneumoniae; and OXA488 and NDM6 in Pseudomonas aeruginosa-reliably predicted drug-resistance phenotype...Additionally, mNGS shows good consistency with traditional culture and can predict drug-resistant phenotypes to guide targeted antibiotic therapy for early-stage post-transplant pulmonary infection after liver transplantation. Patients whose antibiotic therapy is based on mNGS results have experienced decreased mortality rates and overall improved prognosis."

Biomarker • Journal • Next-generation sequencing • Epstein-Barr Virus Infections • Hepatology • Infectious Disease • Pneumonia • Respiratory Diseases • Transplantation

Development of Oxadiazole-Sulfonamide-Based Compounds as Potential Antibacterial Agents. (PubMed, ACS Omega) - "In this work, substituted 1,2,4-oxadiazoles (OX1-OX27) were screened against five bacterial strains, identified to be OX7 and OX11 as growth inhibitors with minimum inhibitory concentration (MIC) values of 31.25 and 15.75 μg/mL, respectively...These compounds in combination with ciprofloxacin also exhibit synergy against Escherichia coli cells...The synergistic behavior of OX11 with ampicillin showed many fold reductions in MIC values against K. georgiana and Klebsiella pneumoniae multidrug resistant strains...OX11 showed significant changes in the secondary structure of human serum albumin (HSA) in the presence of OX11, enhancing HSA stability. Overall, the study provided a suitable core for further synthetic alterations and development as an antibacterial agent."

Journal • Infectious Disease • Pneumonia

Synthesis and SAR studies of novel 1,2,4-oxadiazole-sulfonamide based compounds as potential anticancer agents for colorectal cancer therapy. (PubMed, Bioorg Chem) - "This iteration resulted in compound OX27 with an almost two-fold increase in antiproliferative effect (IC = 6.0 µM) comparable to the clinical drug doxorubicin and significantly higher potency against CAIX (IC = 0.74 µM). Additionally, OX27 treatment decreases the expression of CAIX, induces apoptosis and ROS production, inhibited colony formation and migration of colon cancer cells. Our studies provide preclinical rational for the further optimization of identified OX27 as a suitable lead for the possible treatment of CRC."

Journal